Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.36
+1.7%		$2.36
$2.03
▼
$4.00
$236.12M1.59174,804 shs76,943 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$4.04
+0.7%		$4.23
$1.29
▼
$5.08
$254.89M1.2784,460 shs296,657 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.19
+0.8%		$1.20
$1.02
▼
$1.88
$62.93M1.34408,233 shs118,448 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$8.85
+1.0%		$8.58
$5.60
▼
$12.25
$257.38M0.63140,879 shs83,713 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
+1.31%-2.11%-8.66%-18.88%+6.91%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+2.82%+6.08%-15.58%+33.67%+149.07%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
+0.85%+4.42%-4.84%-16.31%-22.37%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
+4.91%+13.32%-12.84%+1.27%-22.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.36
+1.7%		$2.36
$2.03
▼
$4.00
$236.12M1.59174,804 shs76,943 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$4.04
+0.7%		$4.23
$1.29
▼
$5.08
$254.89M1.2784,460 shs296,657 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.19
+0.8%		$1.20
$1.02
▼
$1.88
$62.93M1.34408,233 shs118,448 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$8.85
+1.0%		$8.58
$5.60
▼
$12.25
$257.38M0.63140,879 shs83,713 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
+1.31%-2.11%-8.66%-18.88%+6.91%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+2.82%+6.08%-15.58%+33.67%+149.07%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
+0.85%+4.42%-4.84%-16.31%-22.37%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
+4.91%+13.32%-12.84%+1.27%-22.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
2.40
Hold$7.50217.12% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.29
Hold$5.5037.33% Upside
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
2.75
Moderate Buy$4.00233.33% Upside
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.57
Moderate Buy$32.60267.41% Upside

Current Analyst Ratings Breakdown

Latest PMVP, MGNX, RNAC, and ACIU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
AC Immune stock logo
ACIU
AC Immune
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/5/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/5/2026
AC Immune stock logo
ACIU
AC Immune
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
7/29/2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/28/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/10/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.00
7/1/2026
AC Immune stock logo
ACIU
AC Immune
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/30/2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/23/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/12/2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$4.31M55.84N/AN/A$0.54 per share4.38
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$157.08M1.62N/AN/A$0.88 per share4.55
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$1.97 per shareN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$2.80M93.10N/AN/A($4.85) per share-1.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$85.03M-$0.82N/A13.91N/A-245.32%-94.52%-28.30%N/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$1.10N/AN/AN/A-44.79%-147.80%-28.40%8/13/2026 (Estimated)
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%N/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%N/A

Latest PMVP, MGNX, RNAC, and ACIU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.0779N/AN/AN/A$59.14 millionN/A
8/6/2026Q2 2026
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.8779$0.46+$1.3379$0.46$0.18 million$0.16 million
8/5/2026Q2 2026
AC Immune stock logo
ACIU
AC Immune
-$0.1044$0.03+$0.1344$0.03$9.59 million$18.67 million
5/13/2026Q1 2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.57-$0.58-$0.01-$0.58$15.24 million$20.78 million
5/12/2026Q1 2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.41-$0.34+$0.07-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
0.11
0.87
1.02
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
1.90
1.80
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
11.14
11.14
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
7.65
7.65

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
90.20%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
AC Immune stock logo
ACIU
AC Immune
4.60%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
10.15%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
37.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140101.77 million97.09 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
43063.56 million54.92 millionOptionable
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5053.33 million47.92 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6429.38 million18.45 millionOptionable

Recent News About These Companies

Cartesian Therapeutics Announces New Employment Inducement Grants
August 7 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341020/0/en/cartesian-therapeutics-announces-new-employment-inducement-grants.html
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6 at 7:09 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cartesian-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update-1036419003
Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership
August 6 at 7:31 AM  |  quiverquant.comQ
Cartesian Therapeutics (RNAC) Projected to Release Earnings on Thursday
August 5 at 3:56 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30942784
Analysts Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Price Target at $32.60
August 4 at 3:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30939960
Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Zacks Research
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cartesian-therapeutics-nasdaqrnac-raised-to-hold-at-zacks-research-2026-07-31/
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Hold" by Analysts
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cartesian-therapeutics-inc-nasdaqrnac-given-average-recommendation-of-hold-by-analysts-2026-07-30/
Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cartesian-therapeutics-rnac-expected-to-announce-earnings-on-thursday-2026-07-30/
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1% - What's Next?
July 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30925257
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1% - Here's What Happened
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cartesian-therapeutics-nasdaqrnac-shares-down-11-heres-what-happened-2026-07-28/
Cartesian Therapeutics Inc RNAC
July 12, 2026  |  morningstar.comM
Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst
July 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RNAC/pressreleases/3096543/cartesian-therapeutics-rnac-receives-a-rating-update-from-a-top-analyst/
Cartesian Therapeutics Announces New Employment Inducement Grants
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321228/0/en/cartesian-therapeutics-announces-new-employment-inducement-grants.html
New Strong Sell Stocks for July 1st
July 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2945820/new-strong-sell-stocks-for-july-1st?cid=cs-stocknewsapi-ft-tale_of_the_tape|new_zacks_5_rank_stocks-2945820
Cartesian Therapeutics Shareholders Back Directors and Governance Measures
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cartesian-therapeutics-shareholders-back-directors-and-governance-measures?utm_source=marketbeat.com&utm_medium=referral
Cartesian Therapeutics Announces New Employment Inducement Grant
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3311308/0/en/cartesian-therapeutics-announces-new-employment-inducement-grant.html
Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)
June 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2436637/wedbush-sticks-to-their-buy-rating-for-cartesian-therapeutics-rnac/
Cartesian climbs on licensing deal with WestGene for CAR-T therapies
June 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4601842-cartesian-inks-licensing-deal-westgene
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308695/0/en/cartesian-therapeutics-announces-strategic-licensing-agreement-with-westgene-biopharma-to-accelerate-the-development-of-in-vivo-car-t-platform-in-autoimmune-diseases.html
Cartesian Therapeutics (RNAC) Gets a Buy from Wedbush
May 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RNAC/pressreleases/1664342/cartesian-therapeutics-rnac-gets-a-buy-from-wedbush/
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3300928/0/en/cartesian-therapeutics-secures-up-to-150-million-of-non-dilutive-financing-from-k2-healthventures-and-expects-topline-data-from-the-phase-3-aurora-trial-in-first-quarter-2027.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.36 +0.04 (+1.72%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.06 (+2.75%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$4.04 +0.03 (+0.75%)
Closing price 04:00 PM Eastern
Extended Trading
$4.04 0.00 (-0.12%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.19 +0.01 (+0.85%)
Closing price 04:00 PM Eastern
Extended Trading
$1.19 0.00 (0.00%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$8.85 +0.09 (+1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$8.50 -0.35 (-3.94%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas